Roche reports positive study of RoACTEMRA given by subcutaneous injection

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy of the subcutaneous (SC) formulation of RoACTEMRA (tocilizumab, known as ACTE…
Read the full story: Breaking World Pharma News